Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Prothena Corp 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS DUBLIN L2 D02 VK60 IRL

www.prothena.com P: 011-353-1236 F: 353-190-2351

Description:

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A'.'Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.

Key Statistics

Overview:

Market Capitalization, $K 1,155,022
Enterprise Value, $K 534,842
Shares Outstanding, K 53,772
Annual Sales, $ 91,370 K
Annual Net Income, $ -147,030 K
Last Quarter Sales, $ 50 K
Last Quarter Net Income, $ -72,240 K
EBIT, $ -216,240 K
EBITDA, $ -207,830 K
60-Month Beta 0.24
% of Insider Shareholders 28.20%
% of Institutional Shareholders 97.08%
Float, K 38,608
% Float 71.80%
Short Volume Ratio 0.47

Growth:

1-Year Return -69.23%
3-Year Return -54.16%
5-Year Return 103.22%
5-Year Revenue Growth 9,417.71%
5-Year Earnings Growth 23.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.34 on 05/08/24
Next Earnings Date 08/01/24
Earnings Per Share ttm -3.25
EPS Growth vs. Prev Qtr -6.35%
EPS Growth vs. Prev Year -50.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PRTA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.48%
Return-on-Assets % -24.74%
Profit Margin % -160.92%
Debt/Equity 0.00
Price/Sales 11.57
Price/Cash Flow N/A
Price/Book 2.10
Book Value/Share 9.35
Interest Coverage -1.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar